Eric Venker Purchases 200,000 Shares of Roivant Sciences
Roivant Sciences' President Eric Venker bought 200,000 shares, investing $770,000.
Key Points
- Eric Venker, President of Roivant Sciences, bought 200,000 shares at $3.85 each on June 24, 2026, totaling $770,000.
- Roivant Sciences, trading at $34.02 on NasdaqGS, has a market cap of $24.47 billion and a forward P/E ratio of -21.82.
- FMR LLC increased holdings by 12.2 million shares, while Vanguard opened a new position with 20.7 million shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Eric Venker, President and CEO of Immunovant, part of Roivant Sciences Ltd. (NasdaqGS: ROIV), made a significant investment in the company by purchasing 200,000 shares on June 24, 2026. The shares were bought at an average price of $3.85 each, totaling an investment of $770,000. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at Roivant Sciences Ltd.
Eric Venker was active in trading Roivant Sciences shares around June 24, 2026. On that date, he bought 200,000 shares at $3.85 each. Additionally, Venker sold 200,000 shares at $33.16 in a planned transaction, and another 200,000 shares with no price disclosed. Other insider activities included Chief Accounting Officer Jennifer Humes selling 3,582 shares at $31.43, and CFO Richard Pulik selling 2,129 shares at the same price, both on June 20, 2026.
Other Institutional Activity in Roivant Sciences
Institutional investors have also been active with Roivant Sciences. FMR LLC grew its holdings by 12,201,789 shares, reaching a total of 77,981,253 shares valued at approximately $2.16 billion. Morgan Stanley reduced its position by 6,531,228 shares, ending with 51,828,325 shares worth about $1.44 billion. BlackRock, Inc. added 3,083,785 shares, bringing its total to 44,254,260 shares valued at $1.23 billion. Meanwhile, UBS Group AG increased its stake by 4,228,680 shares, totaling 22,619,472 shares worth $626.6 million. Vanguard Capital Management LLC opened a new position with 20,680,572 shares valued at $572.9 million.
Roivant Sciences Ltd. Stock Down 1.8%
On Saturday, shares of Roivant Sciences Ltd. traded near $34.02 on the NasdaqGS. The company has a market capitalization of approximately $24.47 billion. Although it is not currently profitable, it has a forward P/E ratio of -21.82 and a beta of 1.137, indicating some market volatility. The stock's 52-week range is between $10.71 and $34.68, with a 50-day moving average of $29.46 and a 200-day moving average of $23.96.
$ROIV stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Several analysts have maintained their ratings on Roivant Sciences. On May 26, 2026, Guggenheim maintained a 'buy' rating with a $36.00 price target. Citigroup and TD Cowen also maintained 'buy' ratings with targets of $42.00 and $41.00, respectively, on May 21, 2026. The consensus among analysts is a 'strong buy,' with a mean price target of $39.04 based on 12 analyst opinions.
About Roivant Sciences Ltd.
Roivant Sciences Ltd. is a biopharmaceutical company based in London, United Kingdom, focusing on developing medicines and technologies. Founded in 2014, it operates in the biotechnology sector. The company, led by CEO Mr. Matthew Gline, employs 721 people and has several clinical product candidates, including IMVT-1402 and mosliciguat, targeting various autoimmune and cardiopulmonary diseases.
Bottom Line
Eric Venker's recent purchase of Roivant Sciences shares reflects his confidence in the company's future. Investors closely watch insider transactions like these to gauge the outlook of company leaders. As always, it's important to remember that insider transactions are reported after they occur and may not reflect the current position.
Get Roivant Sciences Ltd. alerts
New 13F filings, insider trades, and analyst moves on $ROIV, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.